Effectiveness and Toxicity of Ivermectin for the Management of COVID-19: A Meta-Analysis
DOI:
https://doi.org/10.56294/hl2025624Keywords:
Ivermectin, COVID-19, meta-analysis, treatment outcomes, publication bias, antiviral therapyAbstract
Ivermectin was recently suggested as a possible COVID-19 therapy, yet its clinical efficacy and safety remain controversial. This meta-analysis systematically reviews studies from the key databases of PubMed, Elsevier, Scopus, and Web of Science using the Boolean operator to effect of ivermectin on various COVID outcomes including symptom reduction, mortality, and side effects. Relevant studies’ data were included and assessed with a random-effects classicalapproximatingStandardized Mean Difference (SMD). We created forest plots to visualize the treatment effect based on several levels of COVID severity and dose and produced funnel plots to assess publication bias. The findings indicate that ivermectin does not provide a significant clinical benefit compared to standard care. Furthermore, the ivermectin group exhibited a higher incidence of adverse effects, raising safety concerns. Current evidence does not support the use of ivermectin as a primary therapy for COVID-19. Well-designed, rigorously controlled studies are essential to identify safer and more effective treatment options.
References
1. Panahi Y, Gorabi AM, Talaei S, Beiraghdar F, Akbarzadeh A, Tarhriz V, Mellatyar H. An overview on the treatment and prevention against COVID-19. Virology Journal. 2023 Feb 8;20(1):23.https://doi.org/10.1016/j.clim.2020.108427 DOI: https://doi.org/10.1186/s12985-023-01973-9
2. Martinez MA. Efficacy of repurposed antiviral drugs: Lessons from COVID-19 . Drug discovery today. 2022 Jul 1; 27(7):1954-60. https://doi.org/10.1016/j.drudis.2022.02.01 DOI: https://doi.org/10.1016/j.drudis.2022.02.012
3. Degtyarev DN. Can the SARS-COV-2 virus be considered a causative agent of TORCH infections in newborn babies? Neonatologiya: novosti, mneniya, obuchenie [Neonatology: News, Opinions, Training]. 2021;9(1):5-7. https://doi.org/10.33029/2308-2402-2021-9-1-5-7 DOI: https://doi.org/10.33029/2308-2402-2021-9-1-5-7
4. Bodaghi A, Fattahi N, Ramazani A. Biomarkers: Promising and valuable tools towards diagnosis, prognosis, and treatment of COVID-19 and other diseases. Heliyon. 2023 Feb 1;9(2).https://doi.org/10.1183/16000617.0138-2021 DOI: https://doi.org/10.1016/j.heliyon.2023.e13323
5. Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G. and Myers, R., 2021. Effectiveness of COVID-19 vaccines against the B. 1.617. 2 (Delta) variant. New England Journal of Medicine, 385(7), pp.585-594.10.1056/NEJMoa2108891 DOI: https://doi.org/10.1056/NEJMoa2108891
6. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, Gower C, Kall M, Groves N, O’Connell AM, Simons D. Effectiveness of COVID-19 vaccines against the Omicron (B. 1.1. 529) variant of concern. MedRxiv. 2021 Dec 14:2021-12.https://doi.org/10.1101/2021.12.14.21267615 DOI: https://doi.org/10.1101/2021.12.14.21267615
7. Thompson MG, Stenehjem E, Grannis S, Ball SW, Naleway AL, Ong TC, DeSilva MB, Natarajan K, Bozio CH, Lewis N, Dascomb K. Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings. New England Journal of Medicine. 2021 Oct 7;385(15):1355-71.DOI: 10.1056/NEJMoa2110362 DOI: https://doi.org/10.1056/NEJMoa2110362
8. Marfe G, Perna S, Shukla AK. Effectiveness of COVID-19 vaccines and their challenges. Experimental and therapeutic medicine. 2021 Dec;22(6):1407. https://doi.org/10.3892/etm.2021.10843 DOI: https://doi.org/10.3892/etm.2021.10843
9. Kavaliunas A, Ocaya P, Mumper J, Lindfeldt I, Kyhlstedt M. Swedish policy analysis for COVID-19 .Health Policy and Technology. 2020 Dec 1;9(4):598-612. https://doi.org/10.1016/j.hlpt.2020.08.009 DOI: https://doi.org/10.1016/j.hlpt.2020.08.009
10. Gulick RM, Pau AK, Daar E, Evans L, Gandhi RT, Tebas P, Ridzon R, Masur H, Lane HC, NIH COVID-19 Treatment Guidelines Panel, Adimora AA. National Institutes of Health COVID-19 treatment guidelines panel: perspectives and lessons learned. Annals of Internal Medicine. 2024 Nov;177(11):1547-57. https://doi.org/10.1016/j.cmi.2023.01.010 DOI: https://doi.org/10.1016/j.cmi.2023.01.010
11. Ngan DK, Xu T, Xia M, Zheng W, Huang R. Repurposing drugs as COVID-19 therapies: A toxicity evaluation. Drug discovery today. 2022 Jul 1;27(7):1983-93. https://doi.org/10.1016/j.drudis.2022.04.001 DOI: https://doi.org/10.1016/j.drudis.2022.04.001
12. Shirazi FM, Mirzaei R, Nakhaee S, Nejatian A, Ghafari S, Mehrpour O. Repurposing the drug, ivermectin, in COVID-19 : toxicological points of view. European Journal of Medical Research. 2022 Feb 5;27(1):21.Sakamuru, S., Huang, R. and Xia, M., 2022. Use of Tox21 Screening Data to Evaluate the COVID-19 Drug Candidates for Their Potential Toxic Effects and Related Pathways. Frontiers in Pharmacology, https://doi.org/10.1186/s40001-022-00645-8 DOI: https://doi.org/10.1186/s40001-022-00645-8
13. Nakamura S, Huang R, Xia M. Use of Tox21 screening data to evaluate the COVID-19 drug candidates for their potential toxic effects and related pathways. Frontiers in Pharmacology. 2022 Jul 14; 13:935399. https://doi.org/10.3389/fphar.2022.935399 DOI: https://doi.org/10.3389/fphar.2022.935399
14. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, Edwards KM, Gandhi R, Muller WJ, O’Horo JC, Shoham S. Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19 (April 2020). Clinical Infectious Diseases. 2024 Jun 15;78(7):e83-102. https://doi.org/10.1093/cid/ciaa478 DOI: https://doi.org/10.1093/cid/ciaa478
15. Yuan Y, Jiao B, Qu L, Yang D, Liu R. The development of COVID-19 treatment. Frontiers in immunology. 2023 Jan 26;14:1125246.https://doi.org/10.3389/fimmu.2023.1125246 DOI: https://doi.org/10.3389/fimmu.2023.1125246
16. Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post–COVID–19 condition. JAMA Internal Medicine. 2023 Jun 1;183(6):554-64.https://doi.org/10.1001/jamainternmed.2023.0743 DOI: https://doi.org/10.1001/jamainternmed.2023.0743
17. McAfee NW, Schumacher JA, Carpenter RK, Ahmad Z. College student mental health, treatment utilization, and reduced enrollment: Findings across a state university system during the COVID-19 pandemic. Journal of American College Health. 2025 Feb 7;73(2):803-12.https://doi.org/10.1080/07448481.2023.2248495 DOI: https://doi.org/10.1080/07448481.2023.2248495
18. Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P, Gao Y, Cui Z, Zhang Q, Meng X, Gui H. VV116 versus nirmatrelvir–ritonavir for oral treatment of COVID-19 . New England Journal of Medicine. 2023 Feb 2;388(5):406-17.https://doi.org/10.1056/NEJMoa2208822 DOI: https://doi.org/10.1056/NEJMoa2208822
19. Konitsioti AM, Laurent S, Ellenberger D, Stahmann A, Rommer P, Haas J, Warnke C. MS treatment trends before, during, and after the COVID-19 pandemic: insights from the German MS Register. Journal of Neurology. 2025 Apr;272(4):294.https://doi.org/10.1007/s00415-025-13010-6 DOI: https://doi.org/10.1007/s00415-025-13010-6
20. Drysdale M, Chang R, Guo T, Duh MS, Han J, Birch H, Sharpe C, Liu D, Kalia S, Van Dyke M, DerSarkissian M. Impact of treatment of COVID-19 with sotrovimab on post-acute sequelae of COVID-19 (PASC): an analysis of National COVID Cohort Collaborative (N3C) data. Infection. 2025 Mar 22:1-7.https://doi.org/10.1007/s15010-025-02505-z DOI: https://doi.org/10.1007/s15010-025-02505-z
21. Pourkarim F, Pourtaghi‐Anvarian S, Rezaee H. Molnupiravir: A new candidate for COVID‐19 treatment. Pharmacology research & perspectives. 2022 Feb;10(1):e00909.https://doi.org/10.1002/prp2.909 DOI: https://doi.org/10.1002/prp2.909
22. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Martín-Quirós A, Caraco Y, Williams-Diaz A, Brown ML, Du J. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. New England Journal of Medicine. 2022 Feb 10;386(6):509-20.https://doi.org/10.1056/NEJMoa2116044 DOI: https://doi.org/10.1056/NEJMoa2116044
23. Lei S, Chen X, Wu J, Duan X, Men K. Small molecules in the treatment of COVID-19. Signal transduction and targeted therapy. 2022 Dec 5;7(1):387.https://doi.org/10.1038/s41392-022-01249-8 DOI: https://doi.org/10.1038/s41392-022-01249-8
24. Wang L, Berger NA, Davis PB, Kaelber DC, Volkow ND, Xu R. COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022. MedRxiv. 2022 Jun 22.https://doi.org/10.1101/2022.06.21.22276724 DOI: https://doi.org/10.1101/2022.06.21.22276724
25. Schulman S, Sholzberg M, Spyropoulos AC, Zarychanski R, Resnick HE, Bradbury CA, Connors JM, Falanga A, Iba T, Kaatz S, Levy JH. ISTH guidelines for antithrombotic treatment in COVID‐19. Journal of Thrombosis and Haemostasis. 2022 Oct 1;20(10):2214-25.https://doi.org/10.1111/jth.15808 DOI: https://doi.org/10.1111/jth.15808
26. Mazza MG, Palladini M, Poletti S, Benedetti F. Post-COVID-19 depressive symptoms: epidemiology, pathophysiology, and pharmacological treatment. CNS drugs. 2022 Jul;36(7):681-702.https://doi.org/10.1007/s40263-022-00931-3 DOI: https://doi.org/10.1007/s40263-022-00931-3
27. Robinson PC, Liew DF, Tanner HL, Grainger JR, Dwek RA, Reisler RB, Steinman L, Feldmann M, Ho LP, Hussell T, Moss P. COVID-19 therapeutics: Challenges and directions for the future. Proceedings of the National Academy of Sciences. 2022 Apr 12;119(15):e2119893119.https://doi.org/10.1073/pnas.2119893119 DOI: https://doi.org/10.1073/pnas.2119893119
28. Caraco Y, Crofoot GE, Moncada PA, Galustyan AN, Musungaie DB, Payne B, Kovalchuk E, Gonzalez A, Brown ML, Williams-Diaz A, Gao W. Phase 2/3 trial of molnupiravir for treatment of Covid-19 in nonhospitalized adults. NEJM evidence. 2022 Jan 25;1(2):EVIDoa2100043.https://doi.org/10.1056/EVIDoa2100043. DOI: https://doi.org/10.1056/EVIDoa2100043
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Abhishek Singla, Kollathur Sudheer , Samir Sahu , Rashmi Mishra , Manisha Chandna, Dheeraj Mane (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
